ASCO® 2024 Insights: "The GIANT Trial (EA2186) - Gem & nab-Paclitaxel vs. 5-FU, Leucovorin, & Liposomal Irinotecan in Older Pts With Treatment-Naïve Metastatic Pancreatic Cancer"

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

0:00

Stream Type LIVE

Remaining Time -0:00

0.5x
0.75x
1x, selected
1.25x
1.5x
1.75x
2x

Chapters

descriptions off, selected

captions settings, opens captions settings dialog
captions off, selected

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

TextColorTransparency

BackgroundColorTransparency

WindowColorTransparency

Font Size

Text Edge Style

Font Family

End of dialog window.

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

This video is featured in the 2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "The GIANT Trial (EA2186) - Gem & nab-Paclitaxel vs. 5-FU, Leucovorin, & Liposomal Irinotecan in Older Pts With Treatment-Naïve Metastatic Pancreatic Cancer"

By 2024 ASCO® Annual Meeting Insights Hub FEATURING Efrat Dotan

0 views

June 7, 2024

Chapters